BNTC
Benitec Biopharma Inc.
There isn't enough reported data to score BNTC yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
BNTC Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Strong |
BNTC's balance sheet is currently strong, but its profitability is under pressure. There isn't enough data to rate its revenue and cash flow.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
BNTC PE Valuation
BNTC has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
BNTC Forward outlook
There aren't enough analyst estimates for BNTC to show an outlook.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
BNTC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.98 | +$0.28 |
BNTC has the edge over HIMS in the latest year-over-year earnings comparison.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
BNTC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2023 | $54K | +13% |
| Q4 2022 | $14K | -44% |
| Q1 2022 | $48K | +4700% |
| Q4 2021 | $25K | +2400% |
| Q1 2021 | $1K | -97% |
| Q4 2020 | $1K | -99% |
| Q3 2020 | $55K | +64% |
BNTC's revenue is shrinking: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2023 | -65000% | N/A |
| Q1 2023 | -8039% | -831 points |
| Q4 2022 | -40071% | -20731 points |
| Q1 2022 | -7208% | +372092 points |
| Q4 2021 | -19340% | +306560 points |
| Q2 2021 | -192750% | -185211 points |
| Q1 2021 | -379300% | -376558 points |
| Q4 2020 | -325900% | -322367 points |
BNTC's operating margin was −65000% last quarter, down 45660 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
BNTC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$5M | +$3.2M |
| Q1 2026 | -$4.5M | -$1.4M |
| Q3 2025 | -$3.4M | +$1.2M |
| Q2 2025 | -$8.2M | -$4.9M |
| Q3 2024 | -$4.6M | -$9K |
| Q4 2023 | -$5.4M | +$478K |
| Q3 2023 | -$4.6M | -$532K |
| Q1 2023 | -$4M | -$607K |
BNTC has the stronger cash trend. Its trailing FCF is down 39% versus its history, compared with HIMS at down 84%.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
BNTC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.4% | +3.4M shares |
| 1 year | +28% | +10.8M shares |
| 3 years | +7634% | +48.7M shares |
| 5 years | +19499% | +49.1M shares |
BNTC has 49M diluted shares, up 28% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2020 | — |
| Q4 2019 | — |
| Q3 2019 | — |
| Q2 2019 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over BNTC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
BNTC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2019 | -4.5x | Net Cash |
BNTC has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
BNTC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.7 | Neutral |
| Stochastic | 20.3 | Neutral |
BNTC's weekly RSI is 41 (neutral) and its Stochastic is 20 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
BNTC PE vs Healthcare Sector
BNTC has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
BNTC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.95 | 1.6% above |
| 20 week MA | $11.1 | 18% below |
| 50 week MA | $11.5 | 21% below |
| 100 week MA | $12.3 | 26% below |
| 200 week MA | $8.98 | 1.2% above |
BNTC has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
BNTC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $116.5 | $52.5 | -55% |
| 2021 | $52.5 | $50.7 | -3.6% |
| 2022 | $50.7 | $2.94 | -94% |
| 2023 | $2.94 | $3.23 | +9.9% |
| 2024 | $3.23 | $12.0 | +272% |
| 2025 | $12.0 | $13.1 | +9.2% |
| 2026 YTD | $13.1 | $9.09 | -31% |
BNTC has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.